Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.055
+0.015 (1.44%)
Aug 13, 2025, 9:44 AM - Market open
Akoya Biosciences Stock Forecast
PYXS's stock price has decreased by -68.39% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts that cover Akoya Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $9.00, which forecasts a 753.08% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $13.
Price Target: $9.00 (+753.08%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 19, 2025.
Analyst Ratings
The average analyst rating for Akoya Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +373.93% | May 19, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +658.29% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +373.93% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 → $5 | Strong Buy | Reiterates | $7 → $5 | +373.93% | Dec 20, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $10 → $8 | Buy | Reiterates | $10 → $8 | +658.29% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
n/a
from 16.15M
Revenue Next Year
n/a
EPS This Year
-1.40
from -1.32
EPS Next Year
-1.22
from -1.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 26.3M | ||
| Avg | n/a | n/a | 6.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.30 | -0.82 | -1.13 | ||
| Avg | -1.40 | -1.22 | -1.26 | ||
| Low | -1.52 | -1.43 | -1.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.